123 related articles for article (PubMed ID: 38364192)
21. Involved-field radiotherapy and intra-Ommaya methotrexate/cytarabine in patients with AIDS-related lymphomatous meningitis.
Chamberlain MC; Dirr L
J Clin Oncol; 1993 Oct; 11(10):1978-84. PubMed ID: 7692000
[TBL] [Abstract][Full Text] [Related]
22. The inability of oral leucovorin to elevate CSF 5-methyl-tetrahydrofolate following high dose intravenous methotrexate therapy.
Allen J; Rosen G; Juergens H; Mehta B
J Neurooncol; 1983; 1(1):39-44. PubMed ID: 6611387
[TBL] [Abstract][Full Text] [Related]
23. Methotrexate-Induced Acute Necrotizing Leukoencephalopathy: Role of Aminophylline?
Muzaffar M; Chai M
Am J Ther; 2017; 24(1):e104-e105. PubMed ID: 27574937
[No Abstract] [Full Text] [Related]
24. Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity.
Haykin ME; Gorman M; van Hoff J; Fulbright RK; Baehring JM
J Neurooncol; 2006 Jan; 76(2):153-7. PubMed ID: 16411025
[TBL] [Abstract][Full Text] [Related]
25. Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity.
Haykin M; Gorman M; van Hoff J; Fulbright R; Baehring J
J Neurooncol; 2006 Jan; 76(2):153-7. PubMed ID: 16132495
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of leukoencephalopathy and its potential cognitive sequelae in cancer patients.
Schroyen G; Meylaers M; Deprez S; Blommaert J; Smeets A; Jacobs S; Sunaert S; Sleurs C; Uyttebroeck A
J Chemother; 2020 Nov; 32(7):327-343. PubMed ID: 32799637
[TBL] [Abstract][Full Text] [Related]
27. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?
Glantz MJ; Cole BF; Recht L; Akerley W; Mills P; Saris S; Hochberg F; Calabresi P; Egorin MJ
J Clin Oncol; 1998 Apr; 16(4):1561-7. PubMed ID: 9552066
[TBL] [Abstract][Full Text] [Related]
28. Salvage Treatment with Intracerebrospinal Fluid Thiotepa in Patients with Leptomeningeal Metastasis After Failure of Methotrexate-based Treatment.
Cho KM; Kim YJ; Kim SH; Kim JW; Lee JO; Han JH; Lee KW; Kim JH; Kim CY; Bang SM; Kim IA; Kim JS; Lee JS
Anticancer Res; 2015 Oct; 35(10):5631-8. PubMed ID: 26408736
[TBL] [Abstract][Full Text] [Related]
29. Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity.
Vezmar S; Schüsseler P; Becker A; Bode U; Jaehde U
Pediatr Blood Cancer; 2009 Jan; 52(1):26-32. PubMed ID: 19006245
[TBL] [Abstract][Full Text] [Related]
30. Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate.
Eichler AF; Batchelor TT; Henson JW
Neuro Oncol; 2007 Jul; 9(3):373-7. PubMed ID: 17522329
[TBL] [Abstract][Full Text] [Related]
31. MRI in methotrexate-related leukoencephalopathy: Disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy.
Oka M; Terae S; Kobayashi R; Sawamura Y; Kudoh K; Tha KK; Yoshida M; Kaneda M; Suzuki Y; Miyasaka K
Neuroradiology; 2003 Jul; 45(7):493-7. PubMed ID: 12761601
[TBL] [Abstract][Full Text] [Related]
32. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
[TBL] [Abstract][Full Text] [Related]
33. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
34. Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy.
Rattanakaemakorn P; Pinyowiwat P; Iamsumang W; Chanprapaph K; Suchonwanit P
Drug Des Devel Ther; 2021; 15():2299-2307. PubMed ID: 34093007
[TBL] [Abstract][Full Text] [Related]
35. Leukoencephalopathy following high-dose iv methotrexate chemotherapy with leucovorin rescue.
Allen JC; Rosen G; Mehta BM; Horten B
Cancer Treat Rep; 1980; 64(12):1261-73. PubMed ID: 6970616
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-6-Mediated Inflammation May Cause Methotrexate-Induced Leukoencephalopathy.
Asano T; Iguchi A; Miyasho T
J Interferon Cytokine Res; 2020 Jul; 40(7):341-348. PubMed ID: 32614271
[TBL] [Abstract][Full Text] [Related]
38. Vascular changes of methotrexate-related disseminated necrotizing leukoencephalopathy.
Suzuki K; Takemura T; Okeda R; Hatakeyama S
Acta Neuropathol; 1984; 65(2):145-9. PubMed ID: 6596829
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of nimustine, cytosine arabinoside, and methotrexate in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy.
Morikawa N; Mori T; Kawashima H; Takeyama M; Abe T; Kobayashi H
Biol Pharm Bull; 2001 Apr; 24(4):436-8. PubMed ID: 11305611
[TBL] [Abstract][Full Text] [Related]
40. Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia.
Mateos MK; Marshall GM; Barbaro PM; Quinn MCJ; George C; Mayoh C; Sutton R; Revesz T; Giles JE; Barbaric D; Alvaro F; Mechinaud F; Catchpoole D; Lawson JA; Chenevix-Trench G; MacGregor S; Kotecha RS; Dalla-Pozza L; Trahair TN
Haematologica; 2022 Mar; 107(3):635-643. PubMed ID: 33567813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
